Lipocine (NASDAQ:LPCN) Stock Passes Above 50 Day Moving Average – What’s Next?

Shares of Lipocine Inc. (NASDAQ:LPCN) crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.28 and traded as high as $2.56. Lipocine shares last traded at $2.34, with a volume of 159,254 shares trading hands.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LPCN. HC Wainwright reissued a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a report on Friday, March 27th. Finally, Wall Street Zen downgraded shares of Lipocine from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $15.00.

Lipocine Price Performance

The company has a market capitalization of $19.28 million, a P/E ratio of -1.25 and a beta of 0.48. The stock’s 50 day simple moving average is $2.28 and its two-hundred day simple moving average is $5.54.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%.The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.16 million. As a group, equities research analysts expect that Lipocine Inc. will post -1.91 earnings per share for the current year.

Insider Activity at Lipocine

In other Lipocine news, Director John W. Higuchi purchased 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 7th. The stock was acquired at an average cost of $2.03 per share, with a total value of $81,200.00. Following the completion of the purchase, the director directly owned 203,797 shares in the company, valued at approximately $413,707.91. This represents a 24.42% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Mahesh V. Patel purchased 25,000 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were acquired at an average cost of $2.03 per share, with a total value of $50,750.00. Following the completion of the purchase, the chief executive officer owned 160,679 shares of the company’s stock, valued at $326,178.37. The trade was a 18.43% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 213,000 shares of company stock valued at $434,600. 6.35% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Lipocine

A number of institutional investors and hedge funds have recently modified their holdings of LPCN. Squadron Capital Management LLC bought a new stake in shares of Lipocine during the fourth quarter worth approximately $4,256,000. Eversept Partners LP bought a new stake in shares of Lipocine during the first quarter worth approximately $2,357,000. Diadema Partners LP bought a new stake in shares of Lipocine during the fourth quarter worth approximately $2,095,000. AIGH Capital Management LLC bought a new stake in shares of Lipocine during the first quarter worth approximately $1,598,000. Finally, Ikarian Capital LLC bought a new stake in shares of Lipocine during the fourth quarter worth approximately $1,602,000. 9.11% of the stock is owned by institutional investors.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.